Dynamic population pharmacokinetic–pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice‐daily dosing of canagliflozin

AIM: Canagliflozin is an SGLT2 inhibitor approved for the treatment of type‐2 diabetes. A dynamic population pharmacokinetic–pharmacodynamic (PK/PD) model relating 24‐h canagliflozin exposure profiles to effects on glycosylated haemoglobin was developed to compare the efficacy of once‐daily and twic...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Clin Pharmacol
Päätekijät: de Winter, Willem, Dunne, Adrian, de Trixhe, Xavier Woot, Devineni, Damayanthi, Hsu, Chyi‐Hung, Pinheiro, Jose, Polidori, David
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2017
Aiheet:
Pharmacokinetic Dynamic Relationships
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5401970/
https://ncbi.nlm.nih.gov/pubmed/28138980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13180
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia